Suzhou Zelgen Biopharmaceuticals Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 0.54%

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) has an Asset Resilience Ratio of 0.54% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 688266 liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥16.20 Million

≈ $2.37 Million USD Cash + Short-term Investments

Total Assets

CN¥3.01 Billion

≈ $440.95 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2024)

This chart shows how Suzhou Zelgen Biopharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. See shareholders equity of Suzhou Zelgen Biopharmaceuticals Co Ltd for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Suzhou Zelgen Biopharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Suzhou Zelgen Biopharmaceuticals Co Ltd market cap and net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥16.20 Million	0.54%
Total Liquid Assets	CN¥16.20 Million	0.54%

Asset Resilience Insights

Limited Liquidity: Suzhou Zelgen Biopharmaceuticals Co Ltd maintains only 0.54% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Suzhou Zelgen Biopharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio

Compare Suzhou Zelgen Biopharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Ascendis Pharma AS F:A71	Biotechnology	0.00%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A SHG:688076	Biotechnology	1.39%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
R&G PharmaStudies Co. Ltd. A SHE:301333	Biotechnology	35.96%
Shanghai Shen Lian Biomedical Corp SHG:688098	Biotechnology	3.87%

Annual Asset Resilience Ratio for Suzhou Zelgen Biopharmaceuticals Co Ltd (2019–2024)

The table below shows the annual Asset Resilience Ratio data for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	1.35%	CN¥40.50 Million ≈ $5.93 Million	CN¥3.00 Billion ≈ $439.67 Million	-3.40pp
2023-12-31	4.75%	CN¥137.02 Million ≈ $20.05 Million	CN¥2.89 Billion ≈ $422.49 Million	-10.18pp
2022-12-31	14.92%	CN¥248.93 Million ≈ $36.43 Million	CN¥1.67 Billion ≈ $244.13 Million	+11.18pp
2021-12-31	3.74%	CN¥65.26 Million ≈ $9.55 Million	CN¥1.75 Billion ≈ $255.49 Million	-19.09pp
2020-12-31	22.83%	CN¥449.85 Million ≈ $65.83 Million	CN¥1.97 Billion ≈ $288.31 Million	+20.96pp
2019-12-31	1.87%	CN¥6.00 Million ≈ $877.99K	CN¥320.27 Million ≈ $46.87 Million	--

pp = percentage points

About Suzhou Zelgen Biopharmaceuticals Co Ltd

SHG:688266 China Biotechnology

Market Cap

$4.03 Billion

CN¥27.53 Billion CNY

Market Cap Rank

#4136 Global

#715 in China

Share Price

CN¥104.00

Change (1 day)

+3.59%

52-Week Range

CN¥75.75 - CN¥133.48

All Time High

CN¥133.48